The Efficacy and Safety of Slentrol® (Dirlotapide), a Novel Microsomal Triglyceride Transfer Protein Inhibitor, Administered Daily for up to 52 Weeks in Overweight Labradors
World Small Animal Veterinary Association World Congress Proceedings, 2007
J. Gossellin; S. Peachey; J. Sherington; T.G. Rowan; S.J. Sunderland
Veterinary Medicine Research and Development, Pfizer Ltd.
Sandwich, Kent, UK


Dirlotapide causes body weight reduction in obese dogs primarily due to reductions in food intake.


To investigate the efficacy and safety of dirlotapide in overweight Labradors in two masked, parallel-design studies.


Study A: 42 dogs randomised to 0.0, 0.025, 0.05, 0.1, 0.2 or 0.4 mg dirlotapide/kg/day orally for 4 weeks. Study B: 72 dogs randomised to nine treatments: placebo (24 weeks); dirlotapide (24 weeks) followed by placebo (28 weeks); or dirlotapide (52 weeks); on diets containing 5%, 10% or 15% fat, offered in excess of maintenance requirements. Dogs were weighed and dirlotapide dose (initially 0.1 mg/kg) was adjusted monthly. After 24 weeks, dosages were reduced to stabilise body weight. Body composition (body fat, lean tissue and bone mineral content) was monitored using dual-energy x-ray absorptiometry. Multiple blood samples were collected for haematology and biochemistry.


Study A: body weight and food intake decreased asymptotically with dose, mean weekly weight losses were 1.13-1.76% at 0.1-0.4 mg/kg. Study B: compared with placebo, dirlotapide resulted in significant mean weekly weight loss (0.86%) and decreased food intake for all diets during 24 weeks (P=0.0001), with mean weight loss ranging between 18.4% and 22.3% across diets after 24 weeks. Fat tissue decreased but lean tissue mass was maintained. Intermittent, mild and self-limiting, emesis and loose stools were observed for dirlotapide and placebo.


Dirlotapide administered daily to dogs for up to 52 weeks was clinically safe and resulted in sustained weight reduction regardless of dietary fat level.

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Jacques Gossellin
Pfizer Ltd - Veterinary Medicine Research and Development
Kent, United Kingdom

MAIN : Abstracts - Oral : Efficacy & Safety of Dirlotapide
Powered By VIN

Friendly Reminder to Our Colleagues: Use of VIN content is limited to personal reference by VIN members. No portion of any VIN content may be copied or distributed without the expressed written permission of VIN.

Clinicians are reminded that you are ultimately responsible for the care of your patients. Any content that concerns treatment of your cases should be deemed recommendations by colleagues for you to consider in your case management decisions. Dosages should be confirmed prior to dispensing medications unfamiliar to you. To better understand the origins and logic behind these policies, and to discuss them with your colleagues, click here.

Images posted by VIN community members and displayed via VIN should not be considered of diagnostic quality and the ultimate interpretation of the images lies with the attending clinician. Suggestions, discussions and interpretation related to posted images are only that -- suggestions and recommendations which may be based upon less than diagnostic quality information.


777 W. Covell Blvd., Davis, CA 95616


  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357